Exact Sciences cancer test meets goal, but disappoints investors

(Reuters) - Exact Sciences Corp said its molecular screening test for colorectal cancer met a late-stage trial goal of detecting the disease in more patients than other commonly used tests, but shares fell 28 percent as the results were not as robust as some were expecting.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/6t9QfA7_bBw/story01.htm

phlebotomist programs phlebotomy online phlebotomy technician school